Trials to treat overcorrected myopia:
This article was originally published in Clinica
Executive Summary
The FDA has given conditional approval to begin a study using Sunrise Technologies' LTK system to treat patients with induced hyperopia after overcorrection from excimer laser treatment for myopia. Theoretically, under 5% of myopic laser treatments carried out by experienced excimer laser operators result in overcorrection. However, an incidence of up to 50% has been recorded amongst less experienced operators. Studies performed outside the US have shown that LTK can correct induced hyperopia with minimal trauma to the patient. VISX and Summit market the only approved photorefractive keratectomy lasers (see front page).